10 Things My Chronic Illness Taught My Children – The New York Times – Paula M. Fitzgibbons – DISABILITY AUG. 16, 2017
My children have a mother with a chronic illness. They live with my rheumatoid arthritis just as much as I do.
I was given my diagnosis when all three of them were young, and since then I’ve spent a lot of time worrying about what the daily uncertainty of my condition would mean to them, and whether it would affect their development.
They are all teenagers now, one getting ready for college, and I can attest that my illness has indeed affected them. Here’s how. Continue reading
FDA Declares CBD ‘Beneficial,’ Wants Your Input ASAP – by Bruce Barcott – August 14, 2017
The United Nations is trying to figure out how to categorize cannabidiol (CBD), a non-psychoactive and medically beneficial cannabinoid contained in cannabis. And UN officials, through the US Food and Drug Administration (FDA), are asking for your help.
The FDA declared that
‘CBD has been shown to be beneficial.’
Now the agency needs your comments to back it up.
All those who have information on, or experience with, the use of CBD as a healing substance are encouraged to comment at this federal website. Continue reading
Study Answers Why Ketamine Helps Depression, Offers Target for Safer Therapy – June 21, 2017
UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine’s rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.
Ketamine is drawing intense interest in the psychiatric field after multiple studies have demonstrated it can quickly stabilize severely depressed patients.
But ketamine – sometimes illicitly used for its psychedelic properties – could also impede memory and other brain functions, spurring scientists to identify new drugs that would safely replicate its antidepressant response without the unwanted side effects. Continue reading
8 Facts about Expired Medications – April, 2017
Yes, it’s fine to take medications long after their expiration date, especially if they’ve been stored properly. That date is only for legal liability purposes.
Many medications are very expensive and people hate to waste them. To avoid a costly visit to the doctor for a new prescription, many people have to consume expired drugs.
Physicians and pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and may not even comment on the safety or effectiveness of using their products beyond the date on the label. Continue reading
Opioids in chronic noncancer pain: More faces from the crowd | Pain Res Manag | Jul-Aug 2012 | C Peter N Watson, MD FRCPC | free full-text PMC3411376
The present article contains 17 case reports of 11 CNCP conditions (followed to 2011) selected to illustrate specific issues from a survey of 84 patients with intractable CNCP treated with opioids and followed every three months for a median of 11 years.
Most patients in the total sample reported 50% or greater relief and a moderate improvement in disability.
Problematic use, tolerance and serious adverse effects, including constipation, were not major issues. Continue reading
Guidelines for the Chronic Use of Opioid Analgesics from State Medical Boards – Opioid Guidelines As Adopted April 2017_FINAL.pdf
Adopted as policy by the Federation of State Medical Boards April 2017
In April 2015, the Federation of State Medical Boards (FSMB) Chair, J. Daniel Gifford, MD, FACP, appointed the Workgroup on FSMB’s Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain to review the current science for treating chronic pain with opioid analgesics and to revise the Model Policy as appropriate.
In updating its existing policy, the FSMB sought input from a diverse group of medical and policy stakeholders that ranged from experts in pain medicine and addiction to government officials and other thought leaders.
This what the CDC should have done as well, but did not. Continue reading
» call MORGAN & MORGAN ..tell your story… refer to chronic pain patient class action PHARMACIST STEVE June 19, 2017 by Steve Ariens
Chronic Pain Patients – Call Now
Morgan & Morgan Lawyers
Ask for the medical malpractice department.
Refer to chronic pain patient class action and tell your story. Continue reading
Let’s not kill pain patients to “save” patients with addiction.
– @StefanKertesz on Twitter
As a physician, I urge caution as we cut back opioids | TheHill | By Dr. Stefan G Kertesz – Mar 28, 2017
“If all we talk about is a pill, for or against,
we are having the wrong conversation.
We don’t take care of prescription pads.
We take care of people.” Continue reading
The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism – Ther Clin Risk Manag – 2015 Mar – free full-text PMC article
The current literature describes the possible risks for bone fracture in chronic analgesics users.
There are three main hypotheses that could explain the increased risk of fracture associated with central analgesics, such as opioids:
1) the increased risk of falls caused by central nervous system effects, including sedation and dizziness;
2) reduced bone mass density caused by the direct opioid effect on osteoblasts; and
3) chronic opioid-induced hypogonadism
The impact of opioids varies by sex and among the type of opioid used (less, for example, for tapentadol and buprenorphine). Continue reading
CMS finalizes 2018 payment and policy updates for Medicare Health and Drug Plans, and releases a Request for Information – 2017-04-03
The final policies are similar to those proposed and discussed in the Advance Notice and draft Call Letter in February but incorporate several changes in response to feedback received during the public comment period.
CMS apparently read our comments and reacted to them, unlike the CDC, which completely ignored input on their opioid prescribing guidelines.
This is the first national policy to give authority back to physicians to manage opioid medications for chronic pain patients. It could be a sign that the medical industry is finally reconsidering its rash generic restrictions on what should be a treatment plan developed by doctors with their patients. Continue reading